New hope for stem cell transplant patients: combo therapy targets GVHD

NCT ID NCT07340723

Recruiting now Disease control Sponsor: Daihong Liu Source: ClinicalTrials.gov ↗

First seen Jan 17, 2026 · Last updated May 22, 2026 · Updated 12 times

Summary

This study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for treating grade II acute graft-versus-host disease (GVHD), a common complication after stem cell transplants. About 168 adults who have had a stem cell transplant for blood cancer and develop GVHD within 100 days will take part. The main goal is to see if the combination leads to a higher rate of complete or partial response by day 28.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEM CELL TRANSPLANT COMPLICATIONS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

Conditions

Explore the condition pages connected to this study.

GVHD, ACUTE GVHD,ACUTE STEM CELL TRANSPLANT COMPLICATIONS STEM CELL TRANSPLANT COMPLICATIONS